MyDrHank Review: The $137 Price Is a Year Paid Up Front

MyDrHank is a telehealth platform selling compounded sermorelin, and it is one of the very few providers we track whose sermorelin page leads with sleep rather than treating it as a footnote to muscle and fat loss. On a site about sleep peptides, that gets our attention. What also got our attention is the price. Every page MyDrHank publishes says "Starting at $137/month" — and $137 is not a monthly price. It is what a month costs if you pay $1,644 up front for a year. The month-to-month rate is $199, and the company prints that number nowhere.

The price: $137 is a year paid up front

This is the finding, so it goes first. MyDrHank sells sermorelin on a four-tier ladder, and only one figure from it ever appears on the website:

• •Monthly — $199 billed each month ($199/month). The real ongoing price if you do not commit.
• •Quarterly — $507 up front ($169/month).
• •Six months — $913 up front ($152/month).
• •Yearly — $1,644 up front ($137/month). This is the advertised number.

So "Starting at $137/month" is accurate arithmetic and a misleading headline: it is the twelve-month prepay rate wearing a per-month suffix. The $199 month-to-month rate is not published on any MyDrHank page — not on the sermorelin lander, not in its FAQ, not in the fine print. You find it at checkout, after you have already been sold on a number that is 31% lower.

Two consequences worth being blunt about. First, if you compare MyDrHank against another provider using the figures each one advertises, you are comparing a year's prepayment against someone else's monthly rate — which is exactly how our price-sorted board would mis-rank it if we took the headline at face value, and why we do not. Second, $1,644 up front is a real commitment to a compounded therapy you have not tried, from a clinician who has not yet assessed you. Sermorelin's most defensible effect shows up in weeks rather than months, so there is no clinical reason a first-time patient needs a twelve-month plan.

The lander adds one more qualifier on top of all of that: "Final pricing depends on the protocol and dose prescribed." So even $199 is an entry rate rather than a quote.

What MyDrHank actually is

MyDrHank is operated by Dr. Hank, LLC — the entity named in its own privacy policy and terms of use, which is more corporate identity than several providers on our board disclose. It runs six product lines: weight loss, longevity, peptides and NAD+, sexual health, hair growth and strength. Sermorelin sits inside the longevity/peptide side of that catalogue. This matters for expectation-setting more than for quality — a platform selling GLP-1s, minoxidil, finasteride, tadalafil and sermorelin off one intake system is a general telehealth operator, not a specialist. Nothing about that is disqualifying; plenty of the providers on our sermorelin comparison are structured the same way. It just means the depth of peptide-specific expertise behind the prescription is not something the site demonstrates, and it does not claim to.

What the sermorelin page does do is commit to a position. It markets deeper, more restorative sleep, improved recovery and lean muscle, steady daytime energy and healthy body composition — sleep first, in that order. Its own explanation of the mechanism is that sermorelin "signals your pituitary gland to release growth hormone in its natural rhythm" rather than replacing the hormone outright. That is a fair description of what a GHRH analogue does, and it is the same mechanism our evidence review of sermorelin for sleep and recovery works through in detail.

The headline is a platform tier, not a sermorelin price

One more detail sharpens the point. The identical ladder — $199 monthly, $137 on the year — prices MyDrHank's NAD+ nasal spray. It is not sermorelin pricing at all; it is a tier the platform applies across products. Two different medicines costing exactly the same at every commitment length tells you the number was set by the business model rather than by the drug.

In the company's favour: a free physician consultation is included with the first order, so neither figure is sitting on top of a separate consult fee the way it does at several providers on our board. It is cash-pay, no insurance, cancel anytime. And at $199 month-to-month, MyDrHank sits mid-table rather than expensive — our price-sorted board has cheaper verified programs, and what sermorelin costs per month explains why the spread is as wide as it is.

The promise that does not travel

This is the kind of thing only a direct comparison surfaces. MyDrHank's GLP-1 FAQ states in writing that "the price stays the same at every dose — no surprise price increases", with no contract. That is a strong, specific, buyer-friendly commitment, and it is one of the better reasons to consider that company's weight-loss line. It appears in that FAQ and nowhere else.

It is not made on the sermorelin lander. The sermorelin page says the opposite in its own words: final pricing depends on the protocol and dose prescribed. So if you arrive at MyDrHank having read about its flat-at-every-dose GLP-1 pricing — or having read a review that repeated it without checking which product it applied to — do not carry that expectation into the sermorelin intake. Ask what the price is at the dose you are actually prescribed, and ask what happens to it if the dose goes up. A commitment made on one product page is not a commitment on another.

No bloodwork required to start

MyDrHank is explicit that bloodwork is not required to begin treatment: the intake is a three-minute questionnaire, a U.S.-licensed clinician reviews it (the site quotes 24 hours), and the prescription ships. There are no in-person visits.

Whether you read that as a feature or a gap depends on what you want the therapy to do. It removes the slowest, most expensive step in starting, and it is a genuine convenience. But it also means starting a growth-hormone-axis therapy with no baseline IGF-1 — no number from before, so no way to demonstrate afterwards that anything moved. IGF-1 is the downstream marker that reflects GH-axis activity and is the standard way response is gauged and monitored¹². We work through why that baseline is worth having, and what to do if your provider does not order one, in sermorelin labs and IGF-1 monitoring. If you go this route, consider getting a baseline drawn yourself before the first injection.

Compounded — and the site says so plainly

There is no FDA-approved finished sermorelin product on the US market, so every legitimate prescription is compounded³⁴. What separates providers is how straightforwardly they tell you that. MyDrHank is at the honest end: its own lander states that sermorelin dispensed through it is a compounded medication prepared by a state-licensed U.S. compounding pharmacy, and that compounded drugs are not FDA-approved and have not been evaluated by the FDA for safety, efficacy or quality. That is a stronger disclosure than several better-known names publish.

The gap is what comes next: the pharmacy is never named. "State-licensed" and "U.S." is the whole of it. Since a compounded product is only as good as the facility that makes it, an unnamed pharmacy is a real unknown — the same one we flag on most of the board. We screened MyDrHank against the FDA warning-letter database on 7 August 2026 and found nothing on record for the company.

Where you can actually get it

The consumer page says only that sermorelin is "available in select U.S. states" and publishes no list, which is unhelpfully vague — you find out by completing the intake. The company's partner terms name six exclusions: Kansas, Louisiana, Mississippi, New Mexico, North Dakota and West Virginia. Treat that as the working answer and confirm it at intake before paying for anything.

What the evidence supports, and what it doesn't

MyDrHank's sleep-first framing is better grounded than most marketing in this category, but it is not unlimited. GHRH given to healthy men does measurably change sleep architecture — the classic work showed increased slow-wave sleep alongside the expected GH release⁵ — and GHRH's role in sleep regulation is well described⁶. That effect is real and it is the honest core of the pitch.

What it is not is a guarantee of the rest. The company's FAQ says many people report improved sleep in the first two to four weeks and body-composition changes around weeks eight to twelve; those are company-stated timelines, not trial endpoints, and our realistic results timeline is where we set expectations against the published record instead. The lander's line that sermorelin "has a strong long-term safety profile" is likewise a marketing characterisation rather than a finding — the honest position is that GHRH analogues raise GH and IGF-1 reliably in the short term, and that modern long-term outcome trials in healthy adults do not exist⁷. Before starting, read who should not take sermorelin and the side effects; the prescription route itself is straightforward but the cancer-history question in particular is not a formality.

Who it suits — and who it doesn't

It suits a reader who wants a low-friction start, is drawn to sermorelin specifically for sleep and recovery, is comfortable that a compounded product from an unnamed pharmacy is what they are buying, and is going in at $199 a month with their eyes open. The free first consult, the named operating entity and the plain compounding disclosure all count in its favour.

It suits you less if you were drawn in by the $137 figure and did not intend to prepay a year, if you want the prescribing pharmacy named, if you want labs built into the program, or if you live in one of the six excluded states. Readers who want a flat published monthly rate rather than a prepay headline will find that comparison laid out on our where to buy sermorelin online page.

Bottom line

MyDrHank earns its place on this board on relevance: it is one of the few providers whose sermorelin marketing leads with sleep, the mechanism it describes is the one the evidence actually supports, its compounding disclosure is better than the category average, and it names the entity behind it. The caveats are equally concrete. Sermorelin here is $199 a month; the advertised $137 means paying $1,644 for a year in advance, and the month-to-month figure appears nowhere on the site. The same ladder prices the company's NAD+ product, so the headline is a platform tier. The flat-at-every-dose promise on its GLP-1 line does not apply here. The pharmacy is unnamed, there is no baseline bloodwork, and six states are excluded. Budget $199, ask what your prescribed dose actually costs, and get an IGF-1 baseline drawn whether or not anyone requires it.